References

1. Thompson W, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 2002;41:1183-1189.
2. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991;17:891-905.
3. Gewanter HL, Baum J. The frequency of juvenile arthritis. J Rheumatol 1989 Apr;16(4):556-7.
4. Jarvis JN, Jiang K, Petty HR, et al. Neutrophils: the forgotten cell in JIA disease pathogenesis. Pediatric Rheumatology 2007, 5:13 doi:10.1186/1546-0096-5-13.
5. Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol (Suppl) 1992 Apr;33:6-10.
6. Cassidy J, Kivlin J, Lindsley C. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006;117(5):1843-1845.
7. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-2294.
8. Lewin SA, Skea ZC, Entwistle V, et al. Interventions for providers to promote a patient-centered approach in clinical consultations. Cochrane Database Syst Rev (4):CD003267, 2001.
9. Michie S, Miles J, Weinman J. Patient centeredness in chronic illness: what is it and does it matter? Patient Educ Couns 51(3):197-206, 2003.
10. Rapoff MA, Lindsley CB, Christophersen ER. Parent perceptions of problems experienced by their children in complying with treatments for juvenile rheumatoid arthritis. Arch Phys Med Rehabil 1985;66:427-9.
11. Lemanek KL, Kamps J, Chung NB. Empirically supported treatments in pediatric psychology: regimen adherence. Journal of Pediatric Psychology;26(5):253-275,2001.
12. Renders CM, et al. Interventions to improve the management of diabetes in primary care, outpatient and community settings: a systematic review. Diabetes Care 24(10):1821-33, 2001.
13. Norris SL, et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med 22(4 Suppl):15-38, 2002.
14. Anderson B, et al. Parental involvement in diabetes management tasks: relationships to blood glucose monitoring adherence and metabolic control in young adolescents with insulin dependent diabetes mellitus. Journal of Pediatrics;130(2):257-65, 1997.
15. Herskowitz RD, et al. Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: immediate and long-term linkages with the family milieu. J Pediatr Psychol;15(4):527- 42, 1990.
16. Gau SSF, Shen HY, Chou MC, et al. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. Journal of Child and Adolescent Psychopharmacology 2006;16(3).
17. Lovell DJ, Glass D, Ranz J, et al. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. Arthritis Rheum 2006;54(7):2235-2242.
18. Olivieri NF, Matsui D, Hermann C, Koren G. Compliance assessed by the medication event monitoring system. Arch Dis Child 1991;66:1399-402.
19. Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003:6:566-73.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
21. Stinson J, et al. Asking the experts: exploring the self-management needs of adolescents with arthritis. Arthritis Care and Research 59;65-72, 2008.
22. Murray E, Burns J, See TS, et al. Interactive health communication applications for people with chronic disease. Cochrane Database Syst Rev (4):CD004272, 2005.
23. Dowd JE, Cimaz R, Fink CW. Nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children. Arthritis Rheum 1995;38(9):1225-31.
24. FDA Arthritis Advisory Meeting, November 2006.
25. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Rheum Dis Clin North Am 2007 Aug;33(3):441-70.
26. Reiff A, Lovell DJ, Adelsberg JV, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol 2006:33(5):985-95.
27. Ruperto N, Kuzmina N, Pachanov ED, et al. A randomized trial of two dose regimen of meloxicam compared to naproxen oral suspension in juvenile idiopathic arthritis. Arthritis Rheum 2005 Feb;52(2):563-72.
28. Gedalia A, Espada G, Johnson P, et al. Efficacy and safety of meloxicam oral suspension in the treatment of juvenile rheumatoid arthritis (JRA): results from a twelve-week active-controlled (naproxen oral suspension), multinational trial (abstract). Arthritis Rheum 2004:50(suppl):S95.
29. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992;26:234-37.
30. Giannini EH. Methotrexate: vital new information about a middle aged drug. J Rheumatol 2002 Oct;29(10):2031-3.
31. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USAUSSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children’s Study Group. N Engl J Med 1992 Apr16;326(16):1043-9.
32. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parental methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004 Jul;50(7):2191-201.
33. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child 2002 Aug;87(2):93- 6.
34. Eberhard BA, Sison MC, Gottlieb BS, et al. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 2004;31:2507-2512.
35. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intraarticular glucocorticoid injections and conventional DMARDs in early rheumatoid arthritis. Two-year clinical and radiographic results from the CIMESTRA Study. Ann Rheum Dis 2007 Sep 18; doi:10.1136/ard.2007.076307.
36. Cahill AM, Cho SS, Baskin KM, et al. Benefit of fluroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. Pediatr Radiol 2007 Jun;37(6):544-8.
37. Bliddal H, Terslev L, Qvistgaard E, et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 2006 Sep-Oct;35(5):341-5.
38. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004 Jul;50(7):2191-201.
39. Rose CD, Sigsen BH, Eichenfield AH, et al. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1990;177:653-9.
40. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008 Jan;58(1):73-81.
41. Ortiz-Alvarez O, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004;31:2501-06.
42. Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006 Jul;73(4):388-95.
43. Kremer JM. Methotrexate update. Scand J Rheumatol 1996;25(6):341-4.
44. Kremer JM, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994 Mar;37(3):316-28.
45. Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. Rheum Dis Clin North Am 2007 May;33(2):319- 43.
46. Foell D, Frosch M, Schulze zur Wiesch A, et al. Methotrexate treatment in juvenile idiopathic arthritis: When is the right time to stop? Ann Rheum Dis 2004;63:206- 8.
47. Schulze zur Wiesch J, Foell D, Frosch M, et al. Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheum 2004;22:368- 73.
48. Rossum MA, van Soesbergen RM, Boers M, et al. Longterm outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007 Nov;66(11):1518- 24.
49. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-769.
50. Reiff A, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006 Jun;54(6):1987-94.
51. Reiff A, et al. Safety and efficacy of over 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2007:56 (suppl):S292.
52. Schiff MH, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo- controlled trial. Arthritis Rheum 2004 Feb;50(2):353-63.
53. Johnsen AK, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006 Apr;33(4):659-64.
54. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005; 32:935-942.
55. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo- controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007 Sep;56(9):3096-106.
56. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007 Nov;18(6):481-6.
57. Lovell DJ, et al. Adalimumab is safe and effective during long term treatment of patients with juvenile rheumatoid arthritis. Results from a 2-year study. Arthritis Rheum 2007;56(suppl);S292.
58. Giannini EH, et al. Efficacy of abatacept in different subpopulations of juvenile idiopathic arthritis: results of a randomized withdrawal study. Arthritis Rheum 2007;56(suppl):S291.
59. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol (2007) 91:319–24.
60. Ruperto N, Giannini EH, Prieur AM, et al. Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis: results of double-blind withdrawal phase. Annals Rheumatic Disease 2007:66(suppl II):87.
61. Pascual V, Allantaz F, Arce E, et al. Role of interleukin- 1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-1486.
62. Pascual V, Allantaz F, Arce E, et al. Dramatic clinical response to IL-1 blockade in systemic onset juvenile arthritis. American College of Rheumatology 2004 meeting; San Antonio, TX; October 16-21, 2004; Abstract L14.
63. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of huamized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005 Mar;52(3):818-25.
64. Woo P, Wilkinson N, Prieur AM, et al. Open-label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of pribciple of the efficacy of IL- 6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7(6):R1281-8.